Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HydroVax-001B WNV

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral InfectionActive, not recruiting

Viral InfectionPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Viral Infection

NCT06745921

Clinical

Trials by Indication[1]

Viral Infection1 trial

A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001B WNV in Healthy Adults

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06745921·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HydroVax-001B WNV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HydroVax-001B WNV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HydroVax-001B WNV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Related News